Navigation Links
Scripps Research scientists awarded $2.2 million to develop treatment for multi-drug addiction
Date:6/9/2011

The Scripps Research Institute has been awarded a $2.2 million grant from the National Institutes of Health (NIH) to develop novel therapeutics for the treatment of addiction to multiple substances in a national effort with the University of Kansas.

The total award is for $3,698,130, with the Florida campus of Scripps Research receiving $2.19 million over five years and the University of Kansas receiving approximately $1.5 million.

According to the National Survey on Drug Use and Health, in 2009 an estimated 21.8 million Americans aged 12 or older had used illicit drugs within the last month, approximately 8.7 percent of the population aged 12 or older, an increase over 2008. Illicit drugs include marijuana/hashish, cocaine (including crack), heroin, hallucinogens, inhalants, and prescription-type psychotherapeutics used nonmedically. Multiple drug use is common among substance abusers, according to the National Institute on Drug Abuse (NIDA).

The grant funds research directed by Scripps Research Associate Professor Laura Bohn to develop new compounds targeting a specific receptor playing a critical role in the persistence of compulsive drug seeking and taking. (Receptors bind substances, triggering certain biological effects.)

"All addictive drugs share certain reinforcing properties that make it difficult to quit and remain abstinent," said Bohn. "There is significant evidence spanning decades that the kappa opioid receptor is a good candidate in terms of disrupting this addictive cycle. Right now we're in the early stages of R&D but we have a lot of confidence in what we've studied so far."

The kappa opioid receptor, which is located on neurons, helps regulate the release of dopamine a neurotransmitter that plays a key role in drug addiction. Drugs of abuse often cause the brain to release large amounts of dopamine, flooding the brain's reward system and reinforcing the addictive cycle.

The basis of the studies proposed in the current award results from years of screening by the Molecular Libraries Probe Production Centers Network supported by the NIH. After screening more than 300,000 small molecule compounds, the group, along with the specialized chemistry center at the University of Kansas, identified five novel chemical candidates for clinical development.

For the next five years, the collaborative research team at Scripps Research and the University of Kansas will work to improve selectivity, potency, efficacy, and bioavailability of these compounds to provide a strong preclinical framework for clinical utilization of new drugs targeting the kappa opioid receptor in the hopes of finding a way to help improve recovery from a variety of addictive drugs.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps Research scientist wins $1.9 million grant to study malaria
2. Scripps Research scientists find way to block stress-related cell death
3. Scripps Research scientists find key mechanism in transition to alcohol dependence
4. Scripps Research scientists create new genetic model of premature aging diseases
5. Scripps Research scientists identify mechanism of long-term memory
6. Scripps Research scientists uncover new DNA role in modifying gene function
7. Scripps Research scientists find dual switch regulates fat formation
8. Common chaperone protein found to work in surprising way, say Scripps Research scientists
9. Dr. Daniel Von Hoff presented with top genomics award from Scripps
10. Scripps Research team discovers new details about medically important protein family
11. Scripps Research scientists develop new test for pluripotent stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by ... Global Forecast to 2022", published by MarketsandMarkets, the market is expected to be ... 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... May 22, 2017 , ... ... row in the Aragon Research Globe™ for Corporate Learning, 2017. , Aragon Research ... and market demand, and effectively perform against those strategies. NetDimensions’ ranking as a ...
(Date:5/23/2017)... ... 2017 , ... Bacterial biofilms, surface adherent communities of bacteria that are encased ... food poisoning and catheter infections to gum disease and the rejection of medical implants. ... dollars per year, there is currently a paucity of means for preventing their formation ...
(Date:5/22/2017)... Pittsburgh, PA (PRWEB) , ... May 22, 2017 ... ... Inc. announced today that it is exhibiting in booth B2 at the Association ... in Pittsburgh, May 22-25. , In addition to demonstrating its Cancer Diagnostic ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs of the ... Of Wales Private Hospital. The procedure was performed on a 46-year-old male patient ... treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is a next-generation ...
Breaking Biology Technology: